Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions

Ductal pancreatic adenocarcinoma is associated with a very poor prognosis and most patients are given palliative care. Chemotherapy in the form of gemcitabine has been found to reduce disease-related pain, and the otherwise frequently occurring weight changes, to increase Karnofsky performance status and quality of life and has also resulted in a modest improvement in survival time. The intracellular uptake of gemcitabine is dependent on nucleoside transporters, predominantly human equilibrative nucleoside transporter-1 (hENT-1), which is over-expressed in human pancreatic adenocarcinoma cells. Cellular resistance to gemcitabine can be intrinsic or acquired during gemcitabine treatment. One of the mechanisms is a decrease in hENT-1 expression. Modifications of gemcitabine not rendering it dependent on the nucleoside transporter may be a successful future mode of chemotherapy treatment, and determination of the nucleoside receptor status at the time of diagnosis could potentially also contribute to a more targeted therapy in the future.

[1]  G. Peters,et al.  Antiproliferative Activity and Mechanism of Action of Fatty Acid Derivatives of Gemcitabine in Leukemia and Solid Tumor Cell Lines and in Human Xenografts , 2004, Nucleosides, nucleotides & nucleic acids.

[2]  S. Liau,et al.  HMGA1 Is a Molecular Determinant of Chemoresistance to Gemcitabine in Pancreatic Adenocarcinoma , 2008, Clinical Cancer Research.

[3]  M. Löhr,et al.  Molecular mechanisms of pancreatic cancer and potential targets of treatment , 2007, Scandinavian journal of gastroenterology.

[4]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[5]  Elisa Giovannetti,et al.  Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non–Small-Cell Lung Cancer Cells , 2005, Molecular Pharmacology.

[6]  G. Peters,et al.  2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. , 1993, Biochemical pharmacology.

[7]  J. Furuse,et al.  Impact of gemcitabine on the treatment of metastatic pancreatic cancer , 2005, Journal of gastroenterology and hepatology.

[8]  Franco Mosca,et al.  Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. , 2006, Cancer research.

[9]  L. Hertel,et al.  Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.

[10]  G. Gallick,et al.  Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players , 2008, Clinical Cancer Research.

[11]  Godefridus J Peters,et al.  Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[12]  M. Monden,et al.  Schedule-dependent Therapeutic Effects of Gemcitabine Combined with Uracil-Tegafur in a Human Pancreatic Cancer Xenograft Model , 2006, Pancreas.

[13]  J. Nilsson,et al.  Gemcitabine Treatment in Pancreatic Cancer – Prognostic Factors and Outcome. , 2007 .

[14]  A. Jazag,et al.  HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. , 2006, Cancer research.

[15]  C. Cass,et al.  The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs , 2007, Cancer and Metastasis Reviews.

[16]  R. Andersson,et al.  Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma. , 2004, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[17]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Chien,et al.  In-vitro and in-vivo anti-cancer activity of a novel gemcitabine–cardiolipin conjugate , 2006, Anti-cancer drugs.

[19]  N. Espat,et al.  Inhibition of Proliferation by Omega-3 Fatty Acids in Chemoresistant Pancreatic Cancer Cells , 2007, Annals of Surgical Oncology.

[20]  R. Andersson,et al.  Predictive factors in pancreatic ductal adenocarcinoma: Role of the inflammatory response , 2007, Scandinavian journal of gastroenterology.

[21]  C. R. Crawford,et al.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.

[22]  A. Arlt,et al.  Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death , 2003, Oncogene.

[23]  John R. Mackey,et al.  The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma , 2004, Clinical Cancer Research.

[24]  G. Peters,et al.  Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. , 1994, Cancer research.

[25]  A. Mazo,et al.  Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  R. Abrams,et al.  HUMAN ENT1 IS PREDICTIVE OF RESPONSE IN PATIENTS WITH PANCREATIC CANCER TREATED WITH GEMCITABINE: RESULTS FROM THE RTOG 9704 PROSPECTIVE RANDOMIZED TRIAL , 2007 .

[27]  G. Peters,et al.  Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. , 1994, Biochemical pharmacology.

[28]  M. Saif,et al.  Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? , 2008, JOP : Journal of the pancreas.

[29]  G. Peters,et al.  Clinical Phase I and Pharmacology Study of Gemcitabine (2', 2'-Difluorodeoxycytidine) Administered in a Two-Weekly Schedule , 2007, Journal of chemotherapy.

[30]  D. Hedley,et al.  Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. , 2000, Cancer research.

[31]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[32]  Bauke Ylstra,et al.  In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. , 2005, Cancer research.

[33]  E. Giovannetti,et al.  Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer , 2006, Molecular Cancer Therapeutics.

[34]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[35]  G. Peters,et al.  Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. , 2002, Molecular cancer therapeutics.

[36]  T. Okumura,et al.  Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells , 2007, British Journal of Cancer.

[37]  U. Persson,et al.  The Cost of Treating Pancreatic Cancer , 2003, Acta oncologica.